The purpose of this study is to test the use of topical imipramine in combination with topical photodynamic therapy's (PDT) effect on the effectiveness and pain immunosuppression following treatment. PDT is a commonly used treatment in dermatology for patients who have many pre-cancers (actinic keratosis or "AK") on their skin. These are both FDA-approved medications, but this study is evaluating their use in combination, which has not been evaluated in the past. The investigators have been doing studies using mice that suggest imipramine might reduce immune system suppression by PDT thus allowing it to work better. Subjects whose provider has decided that they may benefit from PDT to treat their skin due to many AK precancerous lesions will be recruited for this study. Please note that the PDT itself is not experimental, only the imipramine treatment to the skin. There is a separate informed consent for the PDT.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
(Forearm Arm Only): Difference in areas of Candida antigen skin test results with PDT+ imipramine
Timeframe: 7, 30, 90 days post-PDT treatments
(Forearm Arm Only): Difference in redness of Candida antigen skin test results with PDT+ imipramine
Timeframe: 7, 30, 90 days post-PDT treatments
Difference in numbers of precancerous AK skin lesions with PDT and imipramine on the face
Timeframe: 6, 12 months post-PDT treatment